For more than fifteen years, Echosens has developed and sold worldwide its FibroScan^® devices that utilise its unique VCTE™ technology, which is protected worldwide by a portfolio of several patents.

On 18 November 2015, during the Medica Fair in Dusseldorf, Germany, Echosens launched a lawsuit for patent infringement in Germany against Wuxi Hisky Medical Technologies ("Hisky Med"), a Chinese company which manufactures and sells a device branded FibroTouch that Echosens believes infringes upon its patents.

On 20 April 2017, the Regional Court of Dusseldorf (Landsgericht Dusseldorf) rendered its judgement and ruled in favor of Echosens, holding that Hisky Med's devices infringe upon the German part of Echosens main patent protecting the general specifications of FibroScan^®. An appeal may be filed by Hisky Med until 22 May 2017.

Echosens has demonstrated its strong vigilance and determination to protect its intellectual property rights within the context of defending its assets, distributors, employees and shareholders. Echosens will not tolerate infringements of its intellectual property rights and will continue taking any appropriate legal action to protect those rights around the world.

About Echosens - Echosens is an innovative high-technology company based in France. Since its inception, Echosens has been recognized as the world's leading provider of non-invasive diagnostic devices for chronic liver diseases. The company's innovative, non-invasive technologies are recognized for cost effectively assessing and monitoring chronic liver diseases with precision, standardization and repeatability. The Group owns three products lines: FibroScan®, FibroMeter™, FibroView™ which are covered by several families of patents owned by Echosens.